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ABSTRACT
Coxsackievirus B3 (CV-B3) is a cardiovirulent enterovirus that utilizes a 5 untranslated region (5 UTR)
to complete critical viral processes. Here, we directly
compared the structure of a 5 UTR from a virulent
strain with that of a naturally occurring avirulent
strain. Using chemical probing analysis, we identified a structural difference between the two 5 UTRs
in the highly substituted stem-loop II region (SLII).
For the remainder of the 5 UTR, we observed conserved structure. Comparative sequence analysis of
170 closely related enteroviruses revealed that the
SLII region lacks conservation. To investigate independent folding and function, two chimeric CV-B3
strains were created by exchanging nucleotides 104–
184 and repeating the 5 UTR structural analysis. Neither the parent SLII nor the remaining domains of the
background 5 UTR were structurally altered by the
exchange, supporting an independent mechanism of
folding and function. We show that the attenuated
5 UTR lacks structure in the SLII cardiovirulence determinant.
INTRODUCTION
Coxsackievirus B3 (CV-B3) is an agent of serious human
diseases including myocarditis and cardiomyopathy (1–4).
This virus is a member of the Picornaviridae family (Order
Picornavirales, Family Picornaviridae, Genus Enterovirus,
species Human enterovirus B, type: CV-B3) (5). Similar to
other enteroviruses, including the well characterized and
closely related poliovirus (PV), the CV-B3 genome is commonly organized into four major regions: a 742 nucleotide
5 untranslated region (5 UTR), a single open reading frame
encoding a 2185 amino acid polypeptide, a 98 nucleotide
3 UTR and a poly(A) tail (6–8). A 22 amino acid protein
* To

called VPg is covalently linked to the 5 end of the enteroviral genome (9,10). The structure and function of the picornavirus 5 UTR has been studied extensively because it plays
a critical role in all stages of the viral infection cycle.
The 5 UTR of CV-B3 and other enteroviruses can be
divided into seven highly structured RNA domains (11)
that are generally divided into two functionally distinct regions (12–15). One functional region is a highly conserved
5 terminal cloverleaf that encompasses domain I as well
as an adjacent pyrimidine rich single stranded sequence.
The cloverleaf and pyrimidine rich region are required for
positive and negative strand synthesis during viral genome
replication (14–19). The second functional region is composed of domains II–VII and is collectively called the internal ribosomal entry site (IRES). The CV-B3 and PV IRESs
are considered type 1 and are structurally distinct from the
type 2 IRESs, best characterized in encephalomyocarditis
virus and foot-and-mouth disease virus (20,21), or the type
3 IRESs found in Hepatitis A virus (22). Irrespective of
type, the IRES is responsible for initiating cap-independent
translation in picornaviruses (21–23). A large body of evidence shows that the cloverleaf and the IRES derive their
functionality from both primary and higher order RNA
structures (24–26). Previous work with PV also supports
a synergistic interplay between these two major functional
regions (27–29). However, a structure-based mechanism describing how these interactions mediate virus multiplication
and virulence remains enigmatic.
Several virulence determinants have been identified in
the enterovirus genome including regions encoding structural and non-structural proteins such as the capsid proteins VP1–VP4 and the non-structural viral polymerase 3D
(30–32). In addition to coding regions, virulence determinants have been identified in the 5 UTR of CV-B3 as well
as other clinically important and well-studied enteroviruses.
For example, PV, coxsackievirus B1 and human enterovirus
71 all have virulence determinants localized in the 5 UTR

whom correspondence should be addressed. Tel: +1 402 554 3380; Fax: +1 402 554 3532; Email: wtapprich@unomaha.edu


C The Author(s) 2014. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Downloaded from https://academic.oup.com/nar/article-abstract/42/15/10112/2437079 by guest on 20 April 2020

Biology Department, University of Nebraska at Omaha, Omaha, NE 68182, USA, 2 Department of Family Medicine,
University of Nebraska Medical Center, Omaha, NE 68198, USA, 3 Genetics, Cell Biology and Anatomy, University of
Nebraska Medical Center, Omaha, NE 68198, USA and 4 Department of Pathology, University of Colorado Anshutz
Medical Campus, Denver, CO 80045, USA

2 Nucleic Acids Research, 2014

MATERIALS AND METHODS
Viral plasmids
Full-length CV-B3/28 and CV-B3/GA genomic constructs
were engineered and kindly provided by Dr Nora Chapman at the Enterovirus Research Laboratory, University of
Nebraska Medical Center, Omaha, NE, USA. The domain
II chimeras (28 SLII GA and GA SLII 28) were also engineered by Dr Chapman and created by exchanging nucleotides 104–184 in CV-B3/GA and CV-B3/28. The plasmids were modified with the inclusion of a 38 nucleotide ribozyme sequence (ATGAGGCCGAAAGGCCGAAAAC
CCGGTATCCCGGGTTC) upstream of the 5 UTR and a
T7 promoter sequence (TAATACGACTCACTATAGGG)
upstream of the ribozyme. Upon in vitro transcription from
the T7 promoter, the ribozyme sequence self-cleaves to produce the authentic uridine at the 5 end of the UTR (50).
The cleaved transcript does not have VPg.
Plasmid DNA was isolated using Qiagen (Valencia, CA,
USA) QIAprep Spin Miniprep Kit according to the manufacturer’s protocol. The 5 UTR template was generated by
linearizing the plasmids. Restriction enzyme Ecl136II was
used to linearize the plasmids encoding CV-B3/28 5 UTR
sequence (756 bp) and BssHII was used to linearize the plasmids encoding the CV-B3/GA 5 UTR sequence (757 bp).
The sticky ends created by the BssHII digestion were filled
in with Klenow. Digested DNA was purified by phenol and
phenol/chloroform extraction. The digested DNA was precipitated by adding two volumes of 95% ethanol and incubating overnight at −20◦ C. The DNA was then pelleted,
washed with 70% ethanol and resuspended with 21 l of
10 mM Tris, 1 mM EDTA Buffer (TE) pH 7.6.
Viral RNA transcription
In vitro transcriptions were done using a Megascript kit
(Ambion, Austin, TX, USA) according the manufacturer’s
protocol. The transcription reactions used 4 g of digested
template DNA and the total reaction volume was brought
to 80 l. The transcription reactions were incubated for
4 h at 37◦ C. The DNA template was removed by adding
4 l of DNase I provided in the Megascript kit and incubating for 30 min at 37◦ C. The transcription reactions
were stopped with 460 l of RNase free water and 60 l
of 0.5 M-ammonium acetate. The RNA was extracted with
phenol-chloroform-isoamyl alcohol (25:24:1) and precipitated by adding 600 l of isopropyl alcohol and incubating
overnight at −20◦ C. The RNA was pelleted by centrifugation for 20 min at 4◦ C. The RNA was washed with 400 l of
70% ethanol and resuspended with 80 l of TE buffer, pH
7.6. The RNA was stored at −80◦ C.
RNA structural analysis
DMS modifications. DMS modification reactions contained 15 g of RNA in 100 l of DMS/Kethoxal buffer
solution (40 mM K-cacodylate [pH 7.2], 10 mM MgCl2 ,
50 mM NH4 Cl). The RNA was denatured by incubating at
80◦ C for 2 min then slow cooled to 40◦ C to allow the RNA
to fold into its native structure. The DMS modification solution was prepared by diluting 20% DMS with 95% ethanol
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(33–40). The most famous and perhaps best-studied example of 5 UTR virulence determinants are nucleotide positions 472, 480 and 481 in domain V of the PV 5 UTR that
are responsible for the Sabin polio vaccine strains (41–43).
A single nucleotide cardiovirulence determinant in the CVB3 5 UTR at position 234 in domain III has been previously
reported (44,45).
The region connecting domain I and domain II combined
with domain II as shown in the most recent structural model
for the CV-B3 5 UTR (11) has been commonly referred to as
stem loop II (SLII, positions 88–181). SLII has been identified as a virulence determinant in multiple enteroviruses
including CV-B3 (35,37). Chimeric constructs with SLII exchanged between virulent and avirulent strains were used to
characterize SLII as a virulence determinant. Dunn et al.
exchanged SLII (88–181) between the naturally occurring
avirulent CV-B3/CO and virulent CV-B3/AS strains and
showed that cardiovirulence in a murine model follows SLII
of CV-B3/AS (37). Similar results were observed when the
SLII in a non-cardiovirulent echovirus 12 (ECV12) was exchanged with SLII of a full-length infectious clone of CVB3. Once again, cardiovirulence followed SLII of the infectious CV-B3 clone in all the chimeric constructs tested (35).
Additional studies examining different enterovirus species
confirm the role of SLII in virulence (33–40). The present
study investigates a structural mechanism underlying SLIIdependent cardiovirulence.
The generally accepted mechanism for 5 UTR-dependent
virulence attenuation is a mutation or accumulation of mutations that change critical RNA secondary and tertiary
structures. Such structural alterations mediate inefficiencies in viral processes such as genome replication and capindependent translation. This structure-based mechanism
of virulence attenuation has motivated efforts to solve and
compare virulent and avirulent 5 UTR structures (46–49).
Most of these comparisons are made using theoretical approaches, most notably RNA folding algorithms and sequence comparison analysis. These theoretical approaches
are useful and have repeatedly predicted secondary structure differences in virulent and avirulent 5 UTR regions
where the primary sequences are not conserved, including
those in the CV-B3 SLII (34,35,49). These theoretical approaches have further strengthened the model suggesting
that structural alterations in SLII underlie changes in CVB3 virulence phenotypes.
Despite the important contributions made by the theoretical approaches, experimental methods are needed to solve
5 UTR structures. In this study, chemical probing techniques are employed to show a drastic secondary structure
shift in the SLII of the naturally occurring avirulent strain,
CV-B3/GA. These results are in agreement with previous
reports showing that SLII is an enterovirus virulence determinant, but add substantially to the structural underpinnings of that functional role (28,33–38). The chemical probing data show that the avirulent CV-B3/GA SLII is unstructured in contrast to the highly structured SLII in virulent
CV-B3/28.
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CMCT modifications. CMCT modification reactions contained 15 g of RNA in 50 l of CMCT buffer solution (40
mM K-borate [pH 8.0], 10 mM MgCl2 , 50 mM NH4 Cl).
The RNA was denatured by incubating at 80◦ C for 2 min
then slow cooled to 40◦ C to allow the RNA to fold into its
native structure. The CMCT modification solution was prepared by dissolving solid CMCT with CMCT buffer solution for a final concentration of 42 mg/ml. Fifty microliter
of the CMCT modification solution was added to the RNA
and the reaction was incubated at 37◦ C for 10 min. The
CMCT modification reaction was stopped with 300 l of
95% ethanol. Control RNA was subjected to the same steps
in the protocol except 50 l of CMCT buffer was added in
place of the CMCT modification solution.
All modified RNA was precipitated with ethanol and
sodium acetate, pelleted, washed with 70% ethanol and resuspended with aqueous solution. The DMS- and CMCTmodified RNA was resuspended with TE solution (pH 7.6).
The Kethoxal-modified RNA was resuspended with 25 mM
potassium borate solution (pH 7.0).

Figure 1. Chemical probing results for CV-B3/28 and CV-B3/GA SLII.
For all sequencing gels, arrows indicate modified positions and vertical
lines between two nucleotide positions indicate that all positions between
and including the positions shown are modified. Sequencing tracks indicating the nucleotide positions are labelled A, C, G and U. Tracks with chemically modified RNA are labelled (+) and tracks with unmodified RNA
are labelled (−). (A) 12% sequencing gel shows CV-B3/28 SLII region–
positions 80–140. (B) 12% sequencing gel shows CV-B3/GA SLII region–
positions 80–140. (C) 12% sequencing gel shows CV-B3/28 SLII region–
positions 110–190. (D) Chemical probing of CV-B3/GA SLII region–
positions 110–200.

to make the final DMS concentration 2%. The DMS modification solution (2 l) was added to the RNA and incubated
at 37◦ C for 10 min. The modification reaction was stopped
by adding 25 l of solution containing 1 M Tris-HCl (pH
7.5), 1 M ␤-mercaptoethanol, 0.1 M EDTA. Control RNA
was subjected to the same steps in the protocol except 2 l
of DMS/Kethoxal buffer was added in place of the DMS
modification solution.

Oligonucleotide labelling. The modified nucleotides were
identified with reverse transcriptase (RT) primer extension
analysis. A collection of oligonucleotide primers was spaced
along the 5 UTR to provide full coverage. The oligonucleotide primers were 5 end labelled with [32 P] ATP and
T4 polynucleotide kinase. The oligonucleotide labelling reactions contained 100 pmol of oligonucleotide DNA, 4 l
of 5X forward buffer (350 mM Tris-HCl [pH 7.6], 500 mM
KCl, 50 mM MgCl2 , 5 mM 2-mercaptoethanol), 100 Ci of
[␥ -32 P]ATP (10 Ci/l) and 10 units of T4 polynucleotide
kinase. The total volume of the labelling reaction was 20 l.
The reaction was incubated at 37◦ C for 40 min followed by
incubation at 60◦ C for 20 min to inactivate the kinase enzyme. Thirty microliter of TE (pH 7.6) was added to the
labelling reaction to dilute the labelled oligonucleotides to
2 pmol/l.
Annealing reaction. The annealing reaction contained 1
g of modified RNA, 2 l of 5X Annealing buffer (250 mM
Tris-HCl [pH 8.3], 200 mM KCl) and 1 l of 32 P-labelled
oligonucleotide for a total volume of 10 l. The RNA was
denatured by incubating at 80◦ C for 2 min then slow cooled
to 40◦ C.
Extension reaction. The extension reaction contained 2
l of the annealing reaction, 2 l of 2X extension mix
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Kethoxal modifications. Kethoxal modification reactions
contained 15 g of RNA in 100 l of DMS/Kethoxal buffer
solution (40 mM K-cacodylate [pH 7.2], 10 mM MgCl2 ,
50 mM NH4 Cl). The RNA was denatured by incubating
at 80◦ C for 2 min then slow cooled to 40◦ C to allow the
RNA to fold into its native structure. Five microliter of 1.5
M Kethoxal was added to the RNA and the reaction was
incubated at 37◦ C for 10 min. The Kethoxal modification
reaction was stopped by adding 50 l of a solution containing 150 mM sodium acetate, 250 mM potassium borate (pH
7.0). Control RNA was subjected to the same steps in the
protocol except 5 l of DMS/Kethoxal buffer was added in
place of the Kethoxal modifying solution.
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Figure 3. Sequence logo showing conservation between positions 110–136 in 170 aligned 5 UTR sequences. The numbers on the x-axis correspond to
nucleotide positions found in the CV-B3/28 5 UTR. Positions where the alignment shows insertions in the CV-B3/28 sequence are labelled with *. The
level of conservation at each position is measured in bits on the y-axis where two bits indicate the highest level of conservation at each position.

(100 mM Tris-HCl [pH 8.3], 80 mM KCl, 12 mM MgCl2 ,
4 mM of each of the four deoxynucleoside triphosphates
[dATP, dCTP, dGTP, dTTP]) and 1 l (1 unit/l) of avian
myeloblastosis virus (AMV) RT (Life Sciences, St Petersburg, FL, USA). Sequencing ladders were generated by
adding primer annealed unmodified RNA to one of four
different termination mixes (50 mM Tris-HCl [pH 8.3],
40 mM KCl, 6 mM MgCl2 , 1 mM of each deoxynucleoside triphosphate [dATP, dCTP, dGTP, dTTP] and 0.1
mM of one dideoxynucleoside triphosphate [ddATP, ddCTP, ddGTP or ddUTP]) and 1 l (1 unit/l) of (AMV)
RT. All the reaction mixtures were incubated at 40◦ C for 25
min. The extension reactions were stopped by adding 2 l of
solution containing 95% formamide, 20 mM EDTA, 0.05%
bromophenol blue, 0.05% xylene cyanol. The reaction mixtures were stored at −80◦ C.
Gel electrophoresis. The primer extension reactions were
analysed on 12% polyacrylamide sequencing gels. The extension products were electrophoresed through the sequencing gel at constant 60W for 3–6 h with TBE buffer
(90 mM Tris-Borate [pH 8.3], 1 mM EDTA). Mobility
through the sequencing gel was visualized and captured
with a Packard Cyclone phosphorimager (Packard Instrument Company, Meriden, CT, USA).
Sequence comparison. Complete full-length genomes of
170 enteroviruses were obtained from http://www.ncbi.

nlm.nih.gov/nucleotide/. The CV-B3/28 accession number
is AY752944 (49). The CV-B3/GA accession number is
AY673831 (49). The enteroviruses that were included in
the comparison were chosen because their full-genome sequences are available in GenBank. Partial sequences were
not included in the comparison. The sequences were aligned
using Invitrogen Vector NTI Advance 11 (Life Technologies, Grand Island, NY, USA). The aligned sequences were
used to generate a sequence logo using http://weblogo.
berkeley.edu/logo.cgi.
RESULTS
Chemical probing analysis
The three chemical probes employed in this study modify positions on the nucleotide bases that are involved in
Watson–Crick base pairing (51). Primarily, these chemicals
and their modification specificity allow Watson–Crick base
paired positions to be distinguished from non-Watson–
Crick positions. DMS methylates the N1 position of adenosine and the N3 position of cytosine. CMCT methylates
the N3 position of uridine and Kethoxal creates a cyclic
adduct using positions N1 and N2 of guanosine. Bases
are protected from modification when they are involved in
Watson–Crick interactions or when they are located in a
solvent inaccessible region of the folded molecule. Modified nucleotides are identified by RT primer extension reactions. During the RT extension reaction, modified posi-
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Figure 2. Predicted secondary structure model of CV-B3/28 and CV-B3/GA SLII. (A) Predicted secondary structure model of CV-B3/28 SLII. (B) Predicted secondary structure of CV-B3/GA SLII. Enlarged nucleotide positions are substituted or inserted in CV-B3/GA.Modified positions are indicated
with a circle. Closed circles indicate heavily modified positions and open circles indicate moderately modified positions.
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tions will stop the extension. The labelled cDNA fragments
produced from the extension reaction are separated on a
12% polyacrylamide gel. For interpreting the position of
modification, bands in the sequencing tracks (A,C,G,U) migrate one position above bands in the experimental modification tracks due to addition of the dideoxynucleotide in
the sequencing track as compared to RT stopping on the
base prior to the DMS, CMCT or Kethoxal modified nucleotides. All chemical probing experiments were conducted
at least three times on independent preparations of RNA.

Figure 4. Chemical probing results for 28 SLII GA and GA SLII 28
chimeras. Positions 104–180 were exchanged between CV-B3/28 and CVB3/GA. For all sequencing gels, arrows indicate modified positions and
vertical lines between two nucleotide positions indicate that all positions
between and including the positions shown are modified. Sequencing
tracks indicating the nucleotide positions are labelled A, C, G and U.
Tracks with chemically modified RNA are labelled (+) and tracks with unmodified RNA are labelled (−). (A) 12% sequencing gel showing 28 SLII
GA (CV-B3/28 5 UTR with CV-B3/GA SLII). (B) 12% sequencing gel
showing GA SLII 28 (CV-B3/GA 5 UTR with CV-B3/28 SLII). (C) 12%
sequencing gel showing 28 SLII GA. (D) 12% sequencing gel showing GA
SLII 28.

The structure of the SLII region was analysed with chemical probing analysis (Figure 1). A summary of the modification results at each position is displayed on models of SLII
in Figure 2. The C-rich region ranging from positions 90–
100 is shown at the top of Figure 1A and B. A strong stop
at positions 99–100 partially obscures the results for the 90–
100 region in Figure 1A and B. Despite the strong stop, a
lack of reactivity is observed in the DMS lane for both CVB3/28 and CV-B3/GA between positions 90 - 100, indicating that this C-rich region is not accessible to solvent. The
A-U rich region spanning positions 100––110 is partially
protected in both CV-B3/28 and CV-B3/GA (Figure 1A
and B). Positions 102G, 103A, 104U, 105G and 106U are
modified in CV-B3/GA. Likewise, for CV-B3/28, positions
101A, 102A, 103C, 104U, 105G and 106U are accessible.
Heavy modifications were observed in both CV-B3/GA
and CV-B3/28 at positions 110U and 111U (Figure 1A and
B). Just downstream of positions 110U and 111U is the region with the highest density of sequence changes between
the CV-B3/GA and CV-B3/28 5 UTRs. Between positions
118 and 147, 15 of the 30 nucleotides are substituted in CVB3/GA (Figure 2A and B). A major structural difference
between CV-B3/GA and CV-B3/28 is observed in this region, as indicated by the drastic difference in chemical modification patterns in the middle of the gel shown in Figure
1A and B as well as on the top of the gel shown in Figure 1C
and D. In CV-B3/28, only positions 120–127 are modified
and the modifications are weak (Figure 1A and C). In sharp
contrast, every position between 110 and 141, 19 of the 24
positions between 161 and 184 and positions predicted to
pair such as 129G, 130G, 131U, 164G, 166U and 167C are
heavily modified in CV-B3/GA (Figure 1B and D).
Chemical probing results for the entirety of CV-B3/28
and CV-B3/GA SLII are shown in Figure 1C and D. These
results were generated using a primer that is downstream
of SLII and distinct from the primer used to generate the
results shown in Figure 1A and B. The drastic structural
difference between CV-B3/GA and CV-B3/28 in the 110–
130 region is once again clearly shown in the top portion of
Figure 1C and D. Downstream of this region, CV-B3/28
and CV-B3/GA have conserved structure from positions
134–160. This structural conservation occurs despite a continued high frequency of substitutions. Positions 141–146
are predicted to base pair with positions 154–159 to form
the upper helical stem of SLII (according to CV-B3/GA
sequence position numbering) (Figure 2). These positions
are unmodified, matching the model’s predictions for both
CV-B3/28 and CV-B3/GA (Figure 1C and D). Interest-
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Structural comparison of SLII regions
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Figure 5. Chemical probing results for CV-B3/28 and CV-B3/GA domains I and V. For all sequencing gels, arrows indicate modified positions and vertical
lines between two nucleotide positions indicate that all positions between and including the positions shown are modified. Sequencing tracks indicating the
nucleotide positions are labelled A, C, G and U. Tracks with chemically modified RNA are labelled (+) and tracks with unmodified RNA are labelled (−).
(A) 12% sequencing gel showing CV-B3/28 domain I. (B) 12% sequencing gel showing CV-B3/GA domain I. (C) Predicted secondary structure model of
CV-B3/28 domain I. Modified positions are indicated with a circle. Closed circles indicate heavily modified positions and open circles indicate moderately
modified positions. (D) Predicted secondary structure model of CV-B3/GA. Modified positions are indicated with a circle. Closed circles indicate heavily
modified positions and open circles indicate moderately modified positions. Enlarged nucleotide positions are substituted or inserted in CV-B3/GA. The
position with the slash is deleted in CV-B3/GA. (E) 12% sequencing gel showing CV-B3/28 domain V. (F) 12% sequencing gel showing CV-B3/GA domain
V. (G) Predicted secondary structure model of CV-B3/28 domain V. Modified positions are indicated with a circle. Closed circles indicate heavily modified
positions and open circles indicate moderately modified positions. (H) Predicted secondary structure model of CV-B3/GA domain V. Modified positions
are indicated with a circle. Closed circles indicate heavily modified positions and open circles indicate moderately modified positions. Enlarged nucleotide
positions are substituted in CV-B3/GA.
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SLII but fails to form in CV-B3/GA SLII. The frequent and
heavy modification in CV-B3/GA suggests that the only
structure present in CV-B3/GA SLII is the upper stem loop
(positions 142–160, according to CV-B3/GA sequence). On
the other hand, our modification results show that there is
extensive structure in both the upper and lower regions of
SLII in CV-B3/28.
Comparative sequence analysis of SLII

Figure 6. Models for structurally distinct domain II folding in CV-B3/GA
and CV-B3/28. (A) CV-B3/GA. (B) CV-B3/28. The enlarged nucleotide
positions are substituted or inserted in CV-B3/GA.

ingly, 8 of the 12 positions forming the SLII upper stem
are substituted in CV-B3/GA. These substitutions occur in
compensatory pairs that are predicted to maintain Watson–
Crick base pairing. Our probing results confirm that these
compensatory changes do indeed allow conserved helical
structure. The sequence of the apical loop region (147A,
148C, 149A, 150C, 151C, 152A, according to CV-B3/28 sequence position numbering) is identical in CV-B3/28 and
CV-B3/GA and all six nucleotides are similarly accessible
in both 5 UTRs (Figure 1C and D).
The chemical probing results for the 3 side of SLII are
also shown in Figure 1C and D. The upper helical stem, including positions 153–158, is protected in both molecules.
Positions 159–161 are exposed in both CV-B3/GA and CVB3/28, matching the structural models (Figure 2A and B)
that show these positions forming the 3 side of the asymmetric internal loop. For CV-B3/28, positions 163–166 are
protected (Figure 1C). The inaccessibility of CV-B3/28 positions 163–166 further supports the model for a CV-B3/28
domain II lower stem (Figure 2A). In contrast, for CVB3/GA, 165A is the only position in the lower stem region (163–167, according to CV-B3/GA sequence) that is
not modified (Figure 1D). This difference in modification
agrees with the results observed for the 5 side of the SLII
lower stem (Figure 1A and B) where CV-B3/GA is exposed
and CV-B3/28 is protected. Together these results suggest
a lower stem (128–132 and 162–166) forms in CV-B3/28

Structural comparison of SLII chimeras
To further explore the 5 UTR RNA structure of virulent
and avirulent isolates, SLII (104–184) was exchanged between CV-B3/28 and CV-B3/GA to generate the chimeric
constructs 28 SLII GA (CV-B3/28 5 UTR with CV-B3/GA
SLII) and GA SLII 28 (CV-B3/GA 5 UTR with CV-B3/28
SLII). As found in the parent molecules, 28 SLII GA was
heavily modified in the SLII region (Figure 4A and C)
and GA SLII 28 was protected (Figure 4B and D). Thus,
probing results for 28 SLII GA matched that of the nonchimeric CV-B3/GA SLII and probing results for GA SLII
28 matched that of the non-chimeric CV-B3/28. The other
five 5 UTR structural domains in 28 SLII GA and GA SLII
28 were also analysed with chemical probing analysis and
no changes occurred in the structural domains outside of
SLII in either chimera (data not shown).
Structural comparison of domains I, III, IV, V and VI
The structure of domains I, II, III, IV, V and VI for both
CV-B3/28 and CV-B3/GA were determined with chemical
probing analysis. The chemical probing results for domain I
(Figure 5A–D) and domain V (Figure 5E–H) are shown in
Figure 5 as representatives of the overall comparison. No
major structure differences between CV-B3/GA and CVB3/28 were observed in domains I, III, IV, V or VI. Minor
alterations were observed in the structural domains outside
of SLII, however these changes were highly localized when
compared to the clear differences observed in SLII.
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The lack of conservation and the structural differences
between CV-B3/28 and CV-B3/GA in the SLII region
raised questions about this region’s sequence conservation
among other enteroviruses. We compared the sequence of
this region in 170 diverse enteroviruses including coxsackieviruses, polioviruses and numbered enteroviruses. Representatives of Enterovirus A, Enterovirus B and Enterovirus
C were included in the analysis. Only full-length genomes
were included in the alignment. The genomes were aligned
and the region spanning 117–127 was not conserved. This
is illustrated in a sequence logo (Figure 3), where the short
letters correspond to poorly conserved regions and tall letters correspond to highly conserved regions. The CV-B3/28
nucleotide position numbering is shown in the sequence
logo x-axis. Interestingly, the largest single stretch of poor
SLII sequence conservation corresponds to the region with
the most sequence differences between CV-B3/28 and CVB3/GA and also corresponds with the region where we detect major structural differences in the 5 UTRs.
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The region connecting the structural domains I and II together with domain II has been collectively referred to as the
SLII region. SLII is a virulence determinant in several enteroviruses including CV-B3, PV, CVB1 and enterovirus 71
(EV71) (33–40). The importance of SLII to PV neurovirulence was demonstrated in a series of studies showing a drastically reduced PV neurovirulence in mutant strains with
substitutions in positions 128–134 (28,38–40). Chimeric
constructs with SLII exchanged between virulent and avirulent CVB1 strains demonstrated that SLII is also a CVB1
virulence determinant (33). More recently, SLII has been
proven critical to EV71 with similar experiments that observed SLII exchanged chimeric constructs and found virulence is determined by SLII (36).
Avirulent phenotypes have been observed in enterovirus
mutants with substitutions and deletions in several different regions of the 5 UTR (11,49,46). The attenuation phenotype is widely believed to be the result of disruption in
5 UTR secondary and tertiary RNA structures that are required for recruiting cellular and viral protein factors (52–
54). The importance of the 5 UTR secondary and tertiary
structural integrity is widely acknowledged, however there
are only a few studies with experimental data definitively
showing how mutations in the 5 UTR change critical structures (55,56).
In this study, the 5 UTR structure of a virulent CV-B3/28
strain and an avirulent CV-B3/GA strain were compared
using chemical probing analysis (51). CV-B3/GA was an
ideal strain for comparison given its natural attenuation and
previous characterization by Lee et al. (49). In that characterization of CV-B3/GA, energy minimization of RNA
folding (57) was used to predict that the CV-B3/GA SLII
region secondary structure was altered in comparison to
cardiovirulent CV-B3 strains. The experimental results presented here confirm a SLII structural difference between
CV-B3/28 and CV-B3/GA, however they do not return the
same structural alteration predicted by energy minimization. As has been found in other studies of RNA folding,
experimental approaches are required to elucidate the biologically relevant structure (58).
Comparison of the full length naturally folded 5 UTRs
of CV-B3/GA and CV-B3/28 revealed that a drastic structural alteration occurs in the SLII region. CV-B3/28 SLII
includes pairing between positions 128–132 with 162–166
forming a lower stem that does not form in CV-B3/GA
(Figure 6). These results may serve as a starting place to
understanding the SLII structure required for enterovirus
cardiovirulence.
This study also sheds some light on the folding behaviour
of SLII and structural interdependence of the 5 UTR as
a whole. The loosely defined SLII region including positions 104–184 was exchanged between CV-B3/GA and CVB3/28 and the chemical probing analysis of the full length
5 UTR was repeated with the chimeric constructs. Collectively, the chemical probing analysis of the chimeras shows
that the secondary structure of SLII follows the parent
molecule and does not depend on the 5 UTR structures
outside of the SLII region. Similarly the structure of the
5 UTR domains outside of SLII are not influenced by the

SLII exchange. Overall these results show that the 5 UTR
structural domains fold independently. These results also
provide a structure-based explanation to previous reports
showing that cardiovirulence of SLII chimeras follows SLII
of the parent strain. These and past results suggest that SLII
is both structurally and functionally independent as a cardiovirulence determinant.
The natural attenuation of CV-B3/GA and the results of
this study raise interesting questions about the overall role
of SLII in CV-B3 virulence. In addition to further supporting SLII as a cardiovirulence determinant, the results of
this study also suggest that SLII mediates virulence without being critical for viral viability. First, the only structural differences we detected between CV-B3/28 and CVB3/GA occur in SLII with the remainder of the 5 UTR
structure conserved. We acknowledge the limits of chemical probing analysis and that this technique primarily distinguishes between Watson–Crick base paired positions versus non-Watson–Crick base paired positions, however our
results clearly indicate structural conservation among the
other five domains. The maintenance of the structural integrity in the domains outside SLII may therefore be required for viability. Second, we included comparative analysis of 170 enteroviruses including the region where the major
structural alteration is observed. There is no conservation
in the region where the structural alteration occurs, once
again suggesting that the primary structure and the higher
order structures dependent on these primary structures may
not be important to overall enterovirus viability and only
important to cardiovirulence. Finally, the probing analysis
of the chimeras showed that SLII folds independently. The
structural independence of SLII would allow alterations in
this region to occur without altering or undoing structural
elements in other regions of the 5 UTR that are essential for
viability.
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